{"id":4006,"date":"2026-10-29T09:00:00","date_gmt":"2026-10-29T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4006"},"modified":"2026-10-31T12:00:42","modified_gmt":"2026-10-31T16:00:42","slug":"kite-753-trials-placed-on-partial-clinical-hold","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4006","title":{"rendered":"KITE 753 Trials Placed on Partial Clinical Hold"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Kite (Gilead)<\/p>\n

Event Type<\/strong><\/p>\n

Partial clinical hold (earnings call)<\/p>\n

Modality<\/strong><\/p>\n

Autologous bicistronic CD19\/CD20 CAR-T<\/p>\n

Asset<\/strong><\/p>\n

KITE-753 (PALISADES-1, PALISADES-2)<\/p>\n

Target<\/strong><\/p>\n

CD19; CD20<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed or refractory diffuse large B-cell lymphoma<\/p>\n

Summary<\/h4>\n

Gilead disclosed on its 29 October earnings call that PALISADES-1 and PALISADES-2, studying the bicistronic CD19\/CD20 CAR-T KITE-753 in relapsed or refractory diffuse large B-cell lymphoma, are on partial clinical hold while it investigates a safety difference between Phase I and later cohorts. This is a new safety and trial-execution event, not an efficacy readout.<\/p>\n

Kite leadership said grade 3 or 4 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in a small number of patients; it reported no grade 5 events or deaths. The company had voluntarily paused and then aligned with FDA on the partial hold, according to its spokesperson. Kite\u2019s current pipeline page flags both trials and says program timelines await hold resolution. The disclosed manufacturing process is three days. Patient counts, exposure denominator, event timing, management, grade-specific incidence, product attributes and comparator rates were not disclosed.<\/p>\n

Deep Analysis<\/h4>\n

ICANS can reflect CAR expansion, inflammatory signaling, patient and disease factors, construct biology or manufacturing attributes. A difference between Phase I and later cohorts warrants a structured, blinded-by-hypothesis comparison of dose, population, bridging therapy, lymphodepletion, product phenotype and release specifications. The hold does not establish manufacturing causation. CD19\/CD20 dual targeting seeks to reduce antigen escape, but that competitive rationale cannot offset an unresolved severe neurologic risk. The hold affects development timing in second-line and later-line DLBCL; it does not by itself determine the safety profile of the related KITE-363 autoimmune program, which management says continues without the rapid process.<\/p>\n

Company and Product Background<\/h4>\n

DLBCL is an aggressive B-cell lymphoma. KITE-753 is an autologous bicistronic CAR-T designed to recognize CD19 and CD20, two B-cell antigens; dual recognition may address single-antigen escape. PALISADES-1 is Phase II in third-line or later disease and PALISADES-2 is Phase III in second-line disease, as currently labeled by Kite.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> a program-specific process or cohort change raised severe ICANS risk; the phase difference and targeted hold support investigation. Counterevidence: no causal mechanism or denominator is public.<\/li>\n
  • Interpretation B:<\/strong> small-number variability or enrollment mix created an apparent difference; the absence of reported deaths is compatible but does not resolve risk.<\/li>\n
  • Upgrade<\/strong> with a transparent case series, product comparability analysis and FDA-authorized restart. Downgrade<\/strong> with additional severe cases or a persistent imbalance after mitigation. An irreducible severe-ICANS rate at effective doses would falsify<\/strong> broad clinical differentiation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is a high-importance negative development for KITE-753 execution, with the cause and ultimate benefit-risk profile uncertain. The source is company disclosure on a public call, independently reflected on Kite\u2019s current pipeline page; detailed safety data remain unavailable.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for trial progress, uncertain for final safety. Confidence in Facts: high for hold, moderate for event details. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Gilead disclosed on its 29 October earnings call that PALISADES-1 and PALISADES-2, studying the bicistronic CD19\/CD20 CAR-T KITE-753 in relapsed or refractory diffuse large B-cell lymphoma, are on partial clinical hold while it investigates…<\/p>\n","protected":false},"author":1,"featured_media":4016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[583,1308,1309,1043,1187,1307],"class_list":["post-4006","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-car-t","tag-clinical-hold","tag-dlbcl","tag-gilead","tag-kite","tag-kite-753"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4006"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4006\/revisions"}],"predecessor-version":[{"id":4025,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4006\/revisions\/4025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4016"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}